Influence of co-morbidity on renal function assessment by Cockcroft-Gault calculation in lung cancer and mesothelioma patients receiving platinum-based chemotherapy

Lung Cancer

Volumn 73, Issue 3, 2011, Pages 356-360

  Hubner, R A ^a   Goldstein, R ^c   Mitchell, S ^b   Jones, A ^b   Ashley, S ^b   O'Brien, M E R ^b   Popat, S ^b,d  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Co morbidity; Cockcroft Gault; EDTA; Lung cancer; Renal function

Indexed keywords

CARBOPLATIN; CISPLATIN; CREATININE; EDETIC ACID;

ACCURACY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CARCINOID; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; COCKCROFT GAULT CALCULATION; COMORBIDITY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; KIDNEY FUNCTION; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; NEPHROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THYMOMA;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMORBIDITY; CREATININE; DRUG TOXICITY; FEASIBILITY STUDIES; FEMALE; HUMANS; KIDNEY; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK; SENSITIVITY AND SPECIFICITY;

EID: 79960891433     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.01.013     Document Type: Article

References (23)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA Cancer J Clin 2009, 59:225-249.
2. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
3. Hanna N., Bunn P.A., Langer C., Einhorn L., Guthrie T., Beck T., et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006, 24:2038-2043.
4. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
5. Pignon J.P., Tribodet H., Scagliotti G.V., Douillard J.Y., Shepherd F.A., Stephens R.J., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol 2008, 26:3552-3559.
6. Calvert A.H., Newell D.R., Gumbrell L.A., O'Reilly S., Burnell M., Boxall F.E., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989, 7:1748-1756.
7. Chantler C., Garnett E.S., Parsons V., Veall N. Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA. Clin Sci 1969, 37:169-180.
8. Wright J.G., Boddy A.V., Highley M., Fenwick J., McGill A., Calvert A.H. Estimation of glomerular filtration rate in cancer patients. Br J Cancer 2001, 84:452-459.
9. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
10. Marx G.M., Blake G.M., Galani E., Steer C.B., Harper S.E., Adamson K.L., et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 2004, 15:291-295.
11. Yancik R. Population aging and cancer: a cross-national concern. Cancer J 2005, 11:437-441.
12. Janssen-Heijnen M.L., Schipper R.M., Razenberg P.P., Crommelin M.A., Coebergh J.W. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 1998, 21:105-113.
13. de Lemos M.L., Hsieh T., Hamata L., Levin A., Swenerton K., Djurdjev O., et al. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies. Gynecol Oncol 2006, 103:1063-1069.
14. Poole S.G., Dooley M.J., Rischin D. A comparison of bedside renal function estimates and measured glomerular filtration rate (Tc99mDTPA clearance) in cancer patients. Ann Oncol 2002, 13:949-955.
15. Calvert A.H. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel. Semin Oncol 1997, 24. S2-85-S82-90.
16. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999, 130:461-470.
17. Verhave J.C., Fesler P., Ribstein J., du Cailar G., Mimran A. Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index. Am J Kidney Dis 2005, 46:233-241.
18. Simon G.R. Treatment of older patients with non-small-cell lung cancer: walking the therapeutic tightrope. J Clin Oncol 2010, 28:523-526.
19. Gronberg B.H., Sundstrom S., Kaasa S., Bremnes R.M., Flotten O., Amundsen T., et al. Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small cell lung cancer receiving platinum-doublet chemotherapy. Europ J Cancer 2010.
20. Chrischilles E.A., Pendergast J.F., Kahn K.L., Wallace R.B., Moga D.C., Harrington D.P., Kiefe C.I., Weeks J.C., West D.W., Zafar S.Y., Fletcher R.H. Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:620-627.
21. Asmis T.R., Ding K., Seymour L., Shepherd F.A., Leighl N.B., Winton T.L., et al. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada clinical trials group trials. J Clin Oncol 2008, 26:54-59.
22. Jelliffe R.W. Creatinine clearance: bedside estimate. Ann Intern Med 1973, 79:604-605.
23. Murray P.T., Ratian M.J. Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs. J Clin Oncol 2003, 21:2633-2635.